



**Pfizer Limited**

The Capital, 1802 / 1901,  
Plot No. C - 70, G Block, Bandra Kurla Complex,  
Bandra (East), Mumbai 400 051.  
Tel: +91 22 6693 2000 Fax: +91 22 2654 0274

November 25, 2019

The Corporate Relationship Dept.  
BSE Limited  
1<sup>st</sup> Floor, P.J.Towers  
Dalal Street, Fort  
Mumbai - 400 001  
Scrip Code: 500680

The Manager, Listing Dept.  
The National Stock Exchange of India Ltd.  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400 051  
Scrip Symbol: PFIZER

Dear Sirs,

**Sub: Disclosure under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')**

Pursuant to Regulation 23(9) of the Listing Regulations, please find enclosed, disclosure of related party transactions on a consolidated basis, in the format specified in the accounting standards for the half year ended September 30, 2019.

The said disclosure is also available on the website of the Company i.e., [www.pfizerindia.com](http://www.pfizerindia.com).

Please take the above on record.

Thanking you,

Yours truly,  
For PFIZER LIMITED

**Prajeet Nair**  
Company Secretary

Encl: A/a

## PFIZER LIMITED

### DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2019

Currency: Rs. in Crore

#### Related party transactions

Transactions during the half year and balances outstanding as at the half year ended September 30, 2019 with the related parties are as follows:

Currency: Rs. in Crore

No.	Nature of transactions	September 30, 2019			Total
		Ultimate holding company	Companies exercising significant influence	Fellow subsidiaries	
1	Service income	-	-	27.41	27.41
2	Recovery of expenses	-	-	0.10	0.10
3	Purchase of stock-in-trade	-	-	135.67	135.67
4	Purchase of raw / bulk materials	-	-	32.04	32.04
5	Intercompany Liability written back	-	1.42	8.59	10.01
6	Outstanding as at the year end – Due from	-	0.09	21.12	21.21
7	Outstanding as at the year end – Due to	3.93	2.68	214.80	221.41

#### Key Managerial Personnel

Currency: Rs. in Crore

No.	Nature of transactions	September 30, 2019	
1	Remuneration to Key Managerial Personnel*		3.95

\* Excludes amounts payable to Key Managerial Personnel towards Gratuity and Compensated Absences.



## **PFIZER LIMITED**

### **DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2019**

#### **Related party transactions**

**I Names of related parties and description of relationships**

**A Parties where control exists:**

Ultimate holding company  
Pfizer Inc., USA

**B Companies collectively exercising significant influence:**

Pfizer East India B.V., Netherlands  
Wyeth LLC, USA  
Wyeth Holdings Corporation, USA  
John Wyeth & Brother Limited, UK  
Warner Lambert Company, LLC, USA  
Parke Davis & Company, LLC USA  
Pharmacia Corporation, USA  
[Collectively holding 63.92% of the aggregate of equity share capital of the Company]

**C Fellow subsidiaries with whom transactions have taken place during the half year**

Pfizer Products India Private Limited, India  
Pfizer Innovative Supply Point Intl BVBA, Belgium  
Pfizer Service Company BVBA, Belgium  
Pfizer Worldwide Services, Ireland  
Pfizer Overseas LLC - Export Division  
Pfizer Export Company  
Pfizer Enterprises SARL - Sales Division  
Pfizer Global Trading  
Pfizer International LLC  
Pfizer Overseas LLC

**D Key Managerial Personnel**

Mr. S. Sridhar - Managing Director  
Mr. Milind Patil - Whole Time Director  
Mr. Vivek Dhariwal - Whole Time Director  
Mr. R. A. Shah - Independent Director  
Mr. Pradip Shah - Independent Director  
Mr. Uday Khanna - Independent Director  
Mr. Sunil Lalbhai - Independent Director  
Ms. Meena Ganesh - Independent Director

